OBJECTIVES: The in vivo efficacy of ciprofloxacin, gatifloxacin and moxifloxacin were assessed in an experimental Francisella tularensis Schu S4 infection in the BALB/c mouse model. METHODS: Mice were given 100 mg/kg of antibiotic by oral administration twice daily commencing at 6, 24 or 48 h post-exposure and continued for 14 days post-exposure. All mice were challenged subcutaneously with 1 x 10(6) cfu F. tularensis Schu S4 and observed for a period of 56 days. RESULTS: Treatment initiated 6 h post-exposure resulted in 94, 100 and 100% survival for ciprofloxacin, gatifloxacin and moxifloxacin, respectively. When treatment was delayed until 24 h post-exposure the survival rates were ciprofloxacin 67%, gatifloxacin 96% and moxifloxacin 100%. Treatment initiated at 48 h post-exposure resulted in a significant reduction in the survival rate of the ciprofloxacin-treated mice, with 0% survival compared with 84 and 62% for gatifloxacin and moxifloxacin, respectively. Non-treated infected control mice died within 96 h post-exposure. Dexamethasone given at day 42 for 7 days to suppress the animals' immune system caused relapse in all of the treatment groups. CONCLUSIONS: Both gatifloxacin and moxifloxacin were more effective at preventing mortality than ciprofloxacin and could be considered as alternative antibiotics in the treatment of systemic F. tularensis infection.
OBJECTIVES: The in vivo efficacy of ciprofloxacin, gatifloxacin and moxifloxacin were assessed in an experimental Francisella tularensis Schu S4 infection in the BALB/c mouse model. METHODS:Mice were given 100 mg/kg of antibiotic by oral administration twice daily commencing at 6, 24 or 48 h post-exposure and continued for 14 days post-exposure. All mice were challenged subcutaneously with 1 x 10(6) cfu F. tularensis Schu S4 and observed for a period of 56 days. RESULTS: Treatment initiated 6 h post-exposure resulted in 94, 100 and 100% survival for ciprofloxacin, gatifloxacin and moxifloxacin, respectively. When treatment was delayed until 24 h post-exposure the survival rates were ciprofloxacin 67%, gatifloxacin 96% and moxifloxacin 100%. Treatment initiated at 48 h post-exposure resulted in a significant reduction in the survival rate of the ciprofloxacin-treated mice, with 0% survival compared with 84 and 62% for gatifloxacin and moxifloxacin, respectively. Non-treated infected control mice died within 96 h post-exposure. Dexamethasone given at day 42 for 7 days to suppress the animals' immune system caused relapse in all of the treatment groups. CONCLUSIONS: Both gatifloxacin and moxifloxacin were more effective at preventing mortality than ciprofloxacin and could be considered as alternative antibiotics in the treatment of systemic F. tularensis infection.
Authors: Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191
Authors: George Aperis; Beth Burgwyn Fuchs; Christine A Anderson; John E Warner; Stephen B Calderwood; Eleftherios Mylonakis Journal: Microbes Infect Date: 2007-02-24 Impact factor: 2.700
Authors: Riccardo V D'Elia; Thomas R Laws; Alun Carter; Roman Lukaszewski; Graeme C Clark Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Marjorie D Sutherland; Andrew W Goodyear; Ryan M Troyer; Jeffrey C Chandler; Steven W Dow; John T Belisle Journal: Vaccine Date: 2012-05-28 Impact factor: 3.641
Authors: Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191
Authors: Kathleen England; Christopher am Ende; Hao Lu; Todd J Sullivan; Nicole L Marlenee; Richard A Bowen; Susan E Knudson; Dennis L Knudson; Peter J Tonge; Richard A Slayden Journal: J Antimicrob Chemother Date: 2009-09-04 Impact factor: 5.790
Authors: Gary R Klimpel; Tonyia Eaves-Pyles; Scott T Moen; Joanna Taormina; Johnny W Peterson; Ashok K Chopra; David W Niesel; Paige Carness; Judith L Haithcoat; Michelle Kirtley; Abdelhakim Ben Nasr Journal: Vaccine Date: 2008-10-16 Impact factor: 3.641